Abstract
In The Lancet Haematology, Feng Xue and colleagues1 report 1 year of sustained mean factor IX (FIX) activity well into the mild range of haemophilia and sufficient to nearly eliminate bleeding events among ten Chinese participants with haemophilia B who received BBM-H901, an adeno-associated viral (AAV) vector mediating FIX Padua (F9 [Arg338Leu]) gene transfer. This success follows multiple trials of AAV-mediated gene addition for haemophilia B that have adapted the FIX Padua transgene2–5 and demonstrate the therapeutic benefit of using an enhanced functional transgene for haemophilia gene therapy while also adapting lessons learned from previous work in AAV vector design.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
